GlassScriptPhysician profile
Anjuli Desai
NPI 1760648372
$81,858.83
in general payments reported to CMS, 2019-2025
68 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $7,685 · 2021: $27K · 2022: $3,626 · 2023: $7,835 · 2024: $8,244 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $9,238 · Consulting Fee: $4,320 · Travel and Lodging: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,833.33 |
| Food and Beverage | $9,237.65 |
| Consulting Fee | $4,320.00 |
| Travel and Lodging | $824.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $20,386.96 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $17,992.56 | 2019-2025 | Belbuca, Xtampza, Belbuca |
| Redhill Biopharma INC. | $10,191.82 | 2020-2021 | |
| Daiichi Sankyo INC. | $8,002.43 | 2019 | |
| Abbott Laboratories | $5,519.08 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $3,535.29 | 2019-2025 | Intracept |
| Nevro Corp. | $2,082.16 | 2020-2022 | |
| Si-Bone, INC. | $1,994.07 | 2019-2025 | |
| Medtronic, INC. | $1,598.16 | 2022-2025 | Synchromedii, Vanta Adaptivestim, Intellis Adaptivestim |
| Abbvie INC. | $1,260.86 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Curonix LLC | $809.08 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medinc of Texas | $764.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $592.24 | 2021-2025 | Relistor, Trulance |
| Amgen INC. | $575.51 | 2019-2022 | |
| Spinal Simplicity, LLC | $548.04 | 2021-2025 | Ha Minuteman G3-R |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuli Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.